Bayer stock heads into the open after a 0.55% Xetra gain

At the close on September 16, 2026, Bayer stock finished Xetra trading at 48.98 euros, up 0.55 percent, while the DAX rose about 0.65 percent on September 17, 2026. Today, investors focus on the recent FDA approval for Kerendia and its implications for Bayer stock.

Bayer stock closed at 48.98 euros on Xetra on September 16, 2026, marking a 0.55% gain versus the prior session based on official closing data for the BAY001 listing. The move left the shares near the upper half of their recent trading corridor and slightly behind the subsequent advance in the German blue-chip index.

September 16, 2026 in numbers

Bayer AG (ISIN DE000BAY0017) ended Xetra trading on September 16, 2026 at 48.98 euros, corresponding to a daily performance of plus 0.55% and a reported volume of 1,359,264 shares for that session, per Xetra data cited by market overviews. As Ad-hoc-news reported, the session saw Bayer shares firming modestly while staying below the 49-euro mark at the official close. The close remained within a day range that kept the stock comfortably inside its prevailing 52-week band, with the level near 48.98 euros still some distance from both the year’s recent highs and lows.

Context for the stock’s position came from the broader German market. According to a European equity wrap from Capital Futures, the DAX index closed up 0.65% on September 17, 2026, underscoring that large German equities have recently trended higher. Against that backdrop, Bayer’s 0.55% gain on September 16, 2026 placed the stock slightly behind the subsequent index move but broadly aligned with the constructive tone in German blue chips over the week.

FDA approval shapes today’s narrative

The most recent company-specific development for today’s session is a fresh approval for Bayer’s kidney drug finerenone, marketed as Kerendia, by the U.S. Food and Drug Administration. As Bayer announced on September 17, 2026, the FDA approved finerenone for a new indication in patients with chronic kidney disease associated with type 1 diabetes, expanding the drug’s label in the U.S. market. A same-day market report from Finanzen.ch highlighted that Bayer shares traded higher intraday on Xetra in response to the Kerendia news, with the stock at times quoted around 49.15 euros, reflecting a modest positive reaction from investors to the regulatory milestone.

Heading into today’s session, this regulatory development is likely to remain central to the narrative around Bayer stock as market participants gauge the potential incremental revenue contribution from the expanded Kerendia indication and its significance for the company’s pharmaceuticals portfolio. In addition, investors will continue to monitor the performance of the DAX and other European indices, whose recent gains have provided a supportive backdrop for large German names such as Bayer without determining their individual price paths.